Review: Ocular side effects of anti-rheumatic medications: What a rheumatologist should know

Lupus

Volumn 19, Issue 6, 2010, Pages 675-682

  Peponis, V ^a   Kyttaris, V C ^b   Chalkiadakis, S E ^a   Bonovas, S ^c   Sitaras, N M ^c  

^a Athens Eye Hospital   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Drugs; Eye; Hydroxychloroquine; Lupus

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; CORTICOSTEROID; ETANERCEPT; HYDROXYCHLOROQUINE; IBUPROFEN; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; INFLIXIMAB; LEFLUNOMIDE; MELOXICAM; MEPACRINE; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; PREDNISONE; RECOMBINANT ALPHA INTERFERON; RITUXIMAB; ROFECOXIB; SALAZOSULFAPYRIDINE; UNINDEXED DRUG; ANTIMETABOLITE; BONE DENSITY CONSERVATION AGENT;

ALLERGIC CONJUNCTIVITIS; ANTIVIRAL ACTIVITY; ARTHRALGIA; AUTOIMMUNE DISEASE; BLEEDING; BLEPHARITIS; BLINDNESS; BLURRED VISION; BURNING SENSATION; CATARACT; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVITIS; CORNEA EPITHELIUM; CORNEA OPACITY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DELIRIUM; DEPIGMENTATION; DEPRESSION; DIPLOPIA; DISCOID LUPUS ERYTHEMATOSUS; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROOCULOGRAM; ELECTRORETINOGRAM; EYE DISEASE; EYE EDEMA; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; FACIAL NERVE PARALYSIS; FLU LIKE SYNDROME; GLAUCOMA; HUMAN; IMMUNE RESPONSE; INTRACRANIAL HYPERTENSION; INTRAOCULAR PRESSURE; KERATOPATHY; LACRIMATION; LEUKOPENIA; LUPUS VULGARIS; LYMPHOMA; MYOPIA; NEOPLASM; NERVE PARALYSIS; OCULAR PRURITUS; OPTIC NERVE DISEASE; OSTEOPOROSIS; PAIN; PAPILLEDEMA; PATHOGENESIS; PERIORBITAL EDEMA; PHOTOPHOBIA; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PSORIASIS; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINOPATHY; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCLERITIS; SIDE EFFECT; SKIN DISEASE; STEVENS JOHNSON SYNDROME; SUBCAPSULAR CATARACT; SWELLING; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THYROID DISEASE; TUBERCULOSIS; UVEITIS; VISUAL DISORDER; VISUAL IMPAIRMENT; WOUND HEALING IMPAIRMENT; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; ANTIMETABOLITES; ANTIRHEUMATIC AGENTS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG INTERACTIONS; EYE DISEASES; HUMANS; RHEUMATIC DISEASES; SULFASALAZINE;

EID: 77951224329     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309360539     Document Type: Review

References (120)

1. Rousseau GG, Baxter JD, Tomkins GM Glucocorticoid receptors: relations between steroid binding and biological effects. J Mol Biol 1972 ; 67: 99-115.
2. Chrousos GP The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995 ; 332: 1351-1362.
3. Carnahan MC, Goldstein DA Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000 ; 11: 478-483.
4. Waterbury L., Kunysz EA, Beuerman R. Effects of steroidal and non-steroidal anti-inflammatory agents on corneal wound healing. J Ocul Pharmacol 1987 ; 3: 43-54. (Pubitemid 17061580)
5. Haimovici R., Gragoudas ES, Duker JS, et al. Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Ophthalmology 1997 ; 104: 1653-1660. (Pubitemid 28053467)
6. Purdy EP, Ajimal GS Vision loss after lumbar epidural steroid injection. Anesth Analg 1998 ; 86: 1191-1122.
7. Victory RA, Hassett P., Morrison G. Transient blindness following epidural analgesia. Anaesthesia 1991 ; 46: 940-941.
8. Ling C., Atkinson PL, Munton C. Bilateral retinal haemorrhages following epidural injection. Br J Ophthalmol 1993 ; 77: 316-317. (Pubitemid 23177365)
9. Cousins MJ, Bridenbaugh PO Neural blockade in clinical anesthesia and management of pain. 2 nd edn. JB Lippincott ; 1988, pp. 946-950.
10. Fraunfelder FT Hormones and agents affecting hormonal mechanisms. In: Fraunfelder FT (ed.), Drug-induced ocular side effects and drug interactions. Williams & Wilkins ; 1996. p. 288-290.
11. Tripathi RC, Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk. Drugs Aging 1999 ; 15: 439-450.
12. Black RL, Oglesby RB, von Sallman L., et al. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 1960 ; 174: 166-171.
13. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995 ; 98: 196-208.
14. Dluhy RG Effect of inhaled beclomethasone dipropionate and budesonide on adrenal function, shin changes and cataract formation. Respir Med 1998 ; 92: 15-23. (Pubitemid 28401239)
15. Urban RC Jr, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol 1986 ; 31: 102-110. (Pubitemid 17173020)
16. Maiorca R., Cristinelli L., Brunori G., et al. Prospective controlled trial of steroid withdrawal after six months in renal transplant patients treated with cyclosporine. Transplant Proc 1988 ; 20: 121-125.
17. Tarantino A., Aroldi A., Stucchi L., et al. A randomized prospective trial comparing cyclosporine monotherapy with triple drug therapy in renal transplantation. Transplantation 1991 ; 52: 53-57.
18. Ponticelli S., Pisani F., Montagnino G., et al. A randomized study comparing cyclosporine alone versus double and triple therapy in renal transplants. Transplant Proc 1997 ; 29: 290-291. (Pubitemid 27123412)
19. Shun-Shin GA, Brown NP, Bron AJ, et al. Dynamic nature of posterior subcapsular cataracts. Br J Ophthalmol 1989 ; 73: 522-527.
20. Chylack LT Cataracts and inhaled corticosteroids. N Engl J Med 1997 ; 337: 46-48.
21. Karim AK, Jacob TJ, Thompson GM The human lens epithelium; morphologic and ultrastructural changes associated with steroid therapy. Exp Eye Res 1989 ; 48: 215-224.
22. Harding JJ, Crabbe MJC. The lens: development, proteins, metabolism and cataract. In: Orlando DH (ed.), The eye. Vol 1B, 3 rd edn. Academic Press ; 1984, pp. 207-492.
23. McLean JM Use of ACTH and cortisone. Tr Am Ophthalmol Soc 1950 ; 48: 293-296.
24. Tripathi RC, Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk. Drugs Aging 1999 ; 15: 439-450.
25. Skuta GL, Morgan RK Corticosteroid-induced glaucoma. In: Ritch R, Shields MB, Krupin T (eds), The glaucomas, 2 nd edn. Mosby ; 1996, pp. 1177-1188.
26. Garbe E., LeLoner J., Boivin JF, et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open angle glaucoma. JAMA 1997 ; 277: 722-727. (Pubitemid 27106224)
27. Akduman L., Kolker AE, Black DL, et al. Treatment of persistent glaucoma secondary to periocular corticosteroids. Am J Ophthalmol 1996 ; 122: 275-277. (Pubitemid 26271446)
28. Zhang X., Ognibene CM, Clark AF, et al. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta. Exp Eye Res 2007 ; 84: 275-284. (Pubitemid 44958468)
29. Stone EM, Fingert JH, Alward WLM, et al. Identification of a gene that causes primary open angle glaucoma. Science 1997 ; 275: 668-670. (Pubitemid 27061334)
30. Wiggs JL, Allingham RR, Vollrath D., et al. Prevalence of mutations in TIGR/ myocilin in patients with adult and juvenile primary open-angle glaucoma. Am J Hum Genet 1998 ; 63: 1549-1552. (Pubitemid 30418553)
31. Kubota R., Kudoh J., Mashima Y., et al. Genomic organization of the human myocilin gene (MYOC) responsible for primary open angle glaucoma (GLC1A). Biochem Biophys Res Commun 1998 ; 242: 396-400. (Pubitemid 28412439)
32. Armaly MF Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response. Invest Ophthalmol 1965 ; 4: 187-197.
33. Armaly MF Effect of corticosteroids on intraocular pressure and fluid dynamics: The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963 ; 70: 482-491.
34. Becker B., Hahn KA Topical corticosteroids and heredity in primary open angle glaucoma. Am J Ophthalmol 1964 ; 57: 543-551.
35. Paterson G. Studies of the response to topical dexamethasone of glaucoma relatives. Trans Ophthalmol Soc UK 1965 ; 85: 295-305.
36. Podos SM, Becker B., Morton WR High myopia and primary open-angle glaucoma. Am J Ophthalmol 1966 ; 62: 1039-1043.
37. Becker B. Diabetes mellitus and primary open angle glaucoma: the XXVII Edward Jackson Memorial Lecture. Am J Ophthalmol 1971 ; 71: 1-16.
38. Gaston H., Absolon MJ, Thurtle OA, et al. Steroid responsiveness in connective tissue diseases. Br J Ophthalmol 1983 ; 67: 487-490. (Pubitemid 13066619)
39. Black RL, Oglesby RB, Von Sallmann L., Bunim JJ Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 1960 ; 174: 166-171.
40. Palimeris G., Koliopoulos J., Velissaropoulos P. Ocular side effects of indomethacin. Ophthalmologica 1972 ; 164: 339-353.
41. Palimeris G., Koliopoulos J., Velissaropoulos P. Electrophysiological findings in patients treated with indomethacin. Adv Exp Med Biol 1972 ; 24: 323-329.
42. Graham CM, Blach RK Indomethacin retinopathy: case report and review. Br J Ophthalmol 1988 ; 72: 434-438.
43. Groomer AE, Terry JE, Westblom TU Subconjunctival and external hemorrhage secondary to oral anticoagulation. J Am Optom Assoc 1990 ; 61: 770-775.
44. Mortada A., Abboud I. Retinal haemorrhages after prolonged use of salicylates. Br J Ophthalmol 1973 ; 57: 199-200.
45. Sharma VK, Sethuraman G., Minz A. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol 2008 ; 74: 238-240. (Pubitemid 351918878)
46. Fraunfelder FW, Solomon J., Mehelas TJ Ocular adverse effects associated with cyclooxygenase-2 inhibitors. Arch Ophthalmol 2006 ; 124: 277-279. (Pubitemid 43247082)
47. Symmons DP, Salmon M., Farr M., et al. Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis. J Rheumatol 1988 ; 15: 575-579.
48. Magnus JH, Elverland HH, Olsen EG, Husby G. Facial palsy and partial accommodative insufficiency associated with sulphasalazine treatment in a patient with ankylosing spondylitis. Scand J Rheumatol 1993 ; 22: 199-201. (Pubitemid 23233557)
49. Santodomingo-Rubido J., Gilmartin B., Wolffsohn JS Drug-induced bilateral transient myopia with the sulphonamide sulphasalazine. Ophthalmic Physiol Opt 2003 ; 23: 567-570. (Pubitemid 41711054)
50. Fuentes-Páez G., Mendez MC, Montañez J., et al. Conjunctival pigmentation in Stevens-Johnson syndrome. Ann Ophthalmol 2007 ; 39: 152-157. (Pubitemid 350126527)
51. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell co stimulation in patients with psoriasis vulgaris. J Clin Invest 1999 ; 103: 1243-1252.
52. Kremer JM, Westhovens R., Leon M., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003 ; 349: 1907-1915. (Pubitemid 37409707)
53. Aran AA, Putterman C. Treatment of lupus nephritis: facing the era of immunotherapy. Panminerva Med 2008 ; 50: 235-245.
54. Genovese MC, Schiff M., Luggen M., et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008 ; 67: 547-554. (Pubitemid 351498439)
55. Schiff M., Keiserman M., Codding C., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008 ; 67: 1096-1103.
56. Kremer JM, Genant HK, Moreland LW, et al. Results of a two-year follow-up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008 ; 58: 953-963.
57. Ruperto N., Lovell DJ, Quartier P., et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008 ; 372: 383-391.
58. Pescovitz MD Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006 ; 6: 859-666.
59. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005 ; 31: 456-473.
60. Foran JM, Rohatiner AZ, Cunningham D., et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000 ; 18: 317-324. (Pubitemid 30056420)
61. Lassoued S., Zabraniecki L., Marin F., Billey T. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum 2007 ; 36: 262-263. (Pubitemid 46177201)
62. Fonollosa A., Segura A., Giralt J., Garcia-Arumi J. Tuberculous uveitis after treatment with etanercept. Graefes Arch Clin Exp Ophthalmol 2007 ; 245: 1397-1399. (Pubitemid 47278679)
63. Taban M., Dupps WJ, Mandell B., Perez VL Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 2006 ; 14: 145-150. (Pubitemid 43890770)
64. Purvin VA Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 1995 ; 113: 1041-1044.
65. Hayasaka S., Fujii M., Yamamoto Y., et al. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving inteferon alfa. Br J Ophthalmol 1995 ; 79: 150-152.
66. O'Neill DP The eye and liver disorders. Eye 1992 ; 6: 366-370.
67. Baratz KH, Fulcher SF, Bourne WM Hepatitis C-associated keratitis. Arch Ophthalmol 1998 ; 116: 529-530.
68. Fukumoto Y., Shigemitsu T., Kajii N., et al. Abducent nerve paralysis during interferon alpha-2a therapy in a case of chronic active hepatitis C. Intern Med 1994 ; 33: 637-640. (Pubitemid 24341920)
69. Gillies MC, Garrett SK, Shina SM, Morlet N., Taylor HR Topical interferon alpha 2b for corneal haze after excimer laser photorefractive keratectomy. J Cataract Refract Surg 1996 ; 22: 891-900.
70. Leyland M., Torok ME, Acheson J., Foster GR Hepatitis C virus infection is not associated with a marked increase in the prevalence of ophthalmic morbidity. Eye 2000 ; 14: 889-891. (Pubitemid 32040872)
71. Tokai R., Ikeda T., Miyaura T., Sato K. Interferon-associated retinopathy and cystoid macular edema. Arch Ophthalmol 2001 ; 119: 1077-1079. (Pubitemid 32652205)
72. Peres-AlvareZ AF, Jimenez-Alonso J., Reche-Molina I., et al. Retinal vasculitis and vitreitis in a patient with chronic hepatitis C virus. Arch Intern Med 2001 ; 161: 2262. (Pubitemid 32905011)
73. Jain K., Lam WC, Waheeb S., Thai Q., Heathcote J. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 2001 ; 85: 1171-1173. (Pubitemid 32929539)
74. Esmaeli B., Koller C., Papadopoulos N., Romaguera J. Interferon-induced retinopathy in asymptomatic cancer patients. Ophthalmology 2001 ; 108: 858-860. (Pubitemid 32374239)
75. Willson RL, Ross RD, Willson LM, et al. Interferon-associated retinopathy in a young, insulin dependent diabetic patient. Retina 2000 ; 20: 413-415.
76. Norcia F., Di Maria A., Prandini F., Redaelli C. Natural interferon therapy: optic nerve ischemic damage? Ophthalmologica 1999 ; 213: 339-340. (Pubitemid 29469877)
77. Kadayifcilar S., Boyacioglu S., Kart H., Gursoy M., Aydin P. Ocular complications with high-dose interferon alpha in chronic active hepatitis. Eye 1999 ; 13: 241-246. (Pubitemid 29210148)
78. Abe T., Nakajima A., Matsunaga M., Sakuragi S., Komatsu M. Decreased tear lactoferrin concentration in patients with chronic hepatitis C. Br J Ophthalmol 1999 ; 83: 684-687. (Pubitemid 29261657)
79. Manesis EK, Moschos M., Brouzas D., et al. Neurovisual impairment: a frequent complication of alpha-interferon treatment in chronic viral hepatitis. Hepatology 1998 ; 27: 1421-1427. (Pubitemid 28227873)
80. Sugano S., Suzuki T., Watanabe M., et al. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol 1998 ; 93: 2441-2444. (Pubitemid 29018552)
81. Kawano T., Shigehira M., Uto H., et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996 ; 91: 309-313. (Pubitemid 26067340)
82. Guyer DR, Tiedeman J., Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993 ; 111: 350-356. (Pubitemid 23085977)
83. Schulman JA, Liang C., Kooragayala LM, King J. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology 2003 ; 110: 437-442. (Pubitemid 36187441)
84. Hejny C., Sternberg P., Lawson DH, Greiner K., Aaberg TM Jr. Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol 2001 ; 131: 782-787. (Pubitemid 32522649)
85. Yamada H., Mizobuchi K., Isogai Y. Acute onset of ocular complications with interferon. Lancet 1994 ; 343: 914. (Pubitemid 24113640)
86. Kuga K., Hasumura S., Nagamori S., Toda G., Kitahara K. Intraocular hemorrhage developing during interferon therapy. Intern Med 1996 ; 35: 15-18. (Pubitemid 26113129)
87. Al-Tweigeri T., Nabholtz JM, Mackey JR Ocular toxicity and cancer chemotherapy. Cancer 1996 ; 78: 1359-1373. (Pubitemid 26317855)
88. Margileth DA, Poplack DG, Pizzo PA, et al. Blindness during remission in two patients with acute lymphoblastic leukemia: a possible complication of multimodality therapy. Cancer 1997 ; 39: 58-61.
89. Clare G., Colley S., Kennett R., et al. Reversible optic neuropathy associated with low-dose methotrexate therapy. J Neuroophthalmol 2005 ; 25: 109-112. (Pubitemid 40791654)
90. Whittle SL, Hughes RA Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology 2004 ; 43: 267-271. (Pubitemid 38313172)
91. Ponjavic V., Granse L., Stigmar EB, et al. Reduced full-field electroretinogram (ERG) in a patient treated with methotrexate. Acta Ophthalmol Scand 2004 ; 82: 96-99. (Pubitemid 38228672)
92. Razonable RR, Pulido JS, Deziel PJ, et al. Chorioretinitis and vitreitis due to Tropheryma whipplei after transplantation: case report and review. Transpl Infect Dis 2008 ; 10: 413-418.
93. Hassikou H., El Haouri M., Tabache M., et al. Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis. Joint Bone Spine 2008 ; 75: 597-599.
94. de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006 ; 355: 675-684. (Pubitemid 44244538)
95. Valleala H., Laitinen K., Pylkkanen L., et al. Clinical and biochemical response to single infusion of clodronate in active rheumatoid arthritis - a double blind placebo controlled study. Inflamm Res 2001 ; 50: 598-601. (Pubitemid 34028324)
96. Fraunfelder FW, Fraunfelder FT Bisphosphonates and ocular inflammation. N Engl J Med 2003 ; 348: 1187-1188.
97. Fraunfelder FW Ocular side effects associated with bisphosphonates. Drugs Today 2003 ; 39: 829-835. (Pubitemid 38095080)
98. Fraunfelder FW, Fraunfelder FF, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 2003 ; 135: 219-222. (Pubitemid 36151800)
99. Payne JF A postgraduate lecture on lupus erythematosus. Clin J 1894 ; 4: 223-229.
100. Schadewaldt H. Introduction of atebrine into material medica. Dtsch Med Wochenschrift 1975 ; 100: 2583-2585.
101. Green R. A report of fifty cases of malaria treated with atebrin. Lancet 1932 ; 1: 826-829.
102. Schulemann W. Synthetic antimalarial drugs. Br Med J 1932 ; 1: 100-101.
103. Carr RE, Henkind P., Rothfield N., et al. Ocular toxicity of antimalarial drugs: long term follow-up. Am J Ophthalmol 1968 ; 66: 738-744.
104. Ansdell VE, Common JD Corneal changes induced by mepacrine. J Trop Med Hyg 1979 ; 82: 206-207.
105. Chamberlain WP Jr, Boles DJ Edema of cornea precipitated by quinacrine (Atabrine). Arch Ophthalmol 1946 ; 35: 120-134.
106. Hobbs HE, Sorsby A., Freedman A. Retinopathy following chloroquine therapy. Lancet 1959 ; 2: 478-480.
107. Shearer RV, Dubois EL Ocular changes induced by long term hydroxychloroquine (Plaquenil) therapy. Am J Ophthalmol 1967 ; 64: 245-252.
108. Levy GD, Munz SJ, Paschal J., et al. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997 ; 40: 1482-1486. (Pubitemid 27430960)
109. Klinger G., Morad Y., Westall CA, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001 ; 358: 813-814. (Pubitemid 32868737)
110. Yam J., Kwok A. Ocular toxicity of hydroxychloroquine. Hong Kong Med J 2006 ; 12: 294-304. (Pubitemid 44285144)
111. Jones SK Ocular toxicity and hydroxychloroquine: Guidelines for screening. Br J Dermatol 1999 ; 140: 37.
112. Marmor MF, Carr RE, Easterbrook M., Farjo AA, Mieler WF Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002 ; 109: 1377-1382. (Pubitemid 34700934)
113. Marmor MF New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis Rheum 2003 ; 48: 1764.
114. Easterbrook M. Screening for antimalarial toxicity: current concepts. Can J Ophthalmol 2002 ; 37: 325-328. (Pubitemid 35351015)
115. Royal College of Ophthalmologists. http://www.rcophth.ac.uk/docs/ publications/published-guidelines/Hydroxychloroquine-and-Ocular-Toxicity-final- Oct-2009.pdf
116. American College of Rheumatology. Position Statement: Screening for Hydroxychloroquine Retinopathy. http://www.rheumatology.org/publications/ position/hydroxy.asp?aud=prs
117. Grierson DJ Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis 1997 ; 56: 188-190.
118. Johnson MW, Vine AK Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol 1987 ; 104: 139-144.
119. Shroyer NF, Lewis RA, Lupski JR Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy. Am J Ophthalmol 2001 ; 131: 761-766.
120. Wei LC, Chen SN, Ho CL, Kuo YH, Ho JD Progression of hydroxychloroquine retinopathy after discontinuation of therapy: Case report. Chang Gung Med J 2001 ; 24: 329-334.